UNSPSC 51433913: Clevidipine

This classification denotes a calcium channel blocker with the molecular formula C21H23Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19O2GP3B7Q, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester but generally known as clevidipine, which bears US NIH Compound Identifier 153994. European Medicines Agency schedules Clevidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06655MIG.

UNSPSC 51433913 Clevidipine is a Commodity code that covers emergency and critical-care medications supplied to state and local health systems, emergency response agencies, and pharmacy benefit programs. State and local governments procure clevidipine and related advanced life support medications—including labetalol, epinephrine, adenosine, and diltiazem—for use by fire rescue services, hospital systems, and managed pharmacy networks. Issuing bodies span city purchasing departments managing emergency medical services procurement, state health and human services commissions overseeing pharmacy benefit administration, and multistate cooperative purchasing alliances coordinating pharmaceutical supply across participating jurisdictions. The City of Tampa and Texas Health and Human Services Commission appear as active buyers in recent months. These procurements require vendors to meet expiration and shelf-life standards, comply with OSHA Hazard Communication Standards and FDA requirements, maintain relationships with authorized wholesale distributors, and demonstrate pricing flexibility across multiple cost models.

Recent activity appears concentrated in Texas and Florida, with multistate cooperative purchasing coordination through Minnesota. The City of Tampa issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications with a due date of April 8, 2026 and an estimated contract value of $40,000.00, requiring delivery within ten calendar days and a one-year term with renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP (S1070000015802) in January 2026 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with contract effectiveness on July 1, 2026 and a two-year term. Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs, signaling early-stage market research before a formal RFP. The City of Tampa's solicitation includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000.